Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Psyched：5-meo-DMT 治療抑鬱症、提供治療的猶他州醫院、埃隆·馬斯克和 Meta 的影響力
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression
鼻內 5-meo-DMT 臨床試驗爲耐藥性抑鬱症帶來希望
Partners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a Phase 2a study of Beckley's novel formulation of 5-MeO-DMT in Treatment Resistant Depression (TRD.)
合作伙伴Beckley Psytech和atai Life Sciences（納斯達克股票代碼：ATAI）共同宣佈了一項針對貝克利治療耐藥性抑鬱症（TRD）的5-meo-DMT新配方的2a期研究的積極初步結果。
BPL-003 is a synthetic and patent-protected benzoate salt formulation of 5-MeO-DMT (aka mebufotenin) designed for intranasal administration. The open-label study assessed safety, tolerability and efficacy of the compound at a single 10mg dose, alongside psychological support, in patients with moderate-to-severe TRD (who withdrew from concomitant antidepressants.) Learn more.
BPL-003 是一種受專利保護的 5-meo-DMT（又名美布替寧）的合成苯甲酸鹽配方，專爲鼻內給藥而設計。這項開放標籤研究評估了該化合物在單劑量10mg下的安全性、耐受性和療效，以及心理支持，適用於中度至重度TRD患者（已停用聯合抗抑鬱藥）。了解更多。
Utah Hospitals Will Soon Provide...
猶他州醫院...
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間